• FDA Vote on Roxadustat in Anemia of Chronic Kidney Disease americanpharmaceuticalreview
    July 19, 2021
    The FDA Cardiovascular and Renal Drugs Advisory Committee (CRDAC) has voted 13 to 1 that the benefit-risk profile of roxadustat does not support approval for the treatment of anemia in chronic kidney disease (CKD) in non-dialysis dependent (NDD) adult ...
PharmaSources Customer Service